biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO
CERo Therapeutics
CERO THERAPEUTICS HOLDINGS, INC.
CERo Therapeutics clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 201 Haskins Way, 230, South San Francisco, California 94080, US
- Employees
- 17
- Programs
- 47
- Drugs
- 84
- Patents
- 14
CERo Therapeutics projects
14 ClinicalTrials.gov programs sponsored by CERo Therapeutics.
CERo Therapeutics has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BRADI ICO-2023-15
CERO THERAPEUTICS HOLDINGS, INC.
Brain metastases of cancer > brain radionecrosis
1 trial -
ENGIC 06 FRUQUITAS
CERO THERAPEUTICS HOLDINGS, INC.
metastatic oeso-gastric adenocarcinoma
1 trial -
FUNGEMAX
CERO THERAPEUTICS HOLDINGS, INC.
Metastatic pancreatic cancer
1 trial -
GCO-003 TARLANEC
CERO THERAPEUTICS HOLDINGS, INC.
Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)
1 trial -
IFCT-1701
CERO THERAPEUTICS HOLDINGS, INC.
Non small cell lung cancer
1 trial -
IFCT-1805
CERO THERAPEUTICS HOLDINGS, INC.
Non Small Cell Lung Cancer
1 trial -
IFCT-2103
CERO THERAPEUTICS HOLDINGS, INC.
Non small cell lung cancer
1 trial -
MEDI4736 Placebo, DURVALUMAB
CERO THERAPEUTICS HOLDINGS, INC.
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients
1 trial -
NIVOLUMAB for Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
CERO THERAPEUTICS HOLDINGS, INC.
Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
1 trial -
PRODIGE 118-PEHRICCA
CERO THERAPEUTICS HOLDINGS, INC.
Hihg risk of cholangiocarcinoma intra hépatic resectable
1 trial -
PRODIGE 49 -OSCAR
CERO THERAPEUTICS HOLDINGS, INC.
colon cancer and rectal with liver metastasis
1 trial -
PRODIGE 51 - GASTFOX
CERO THERAPEUTICS HOLDINGS, INC.
Locally advanced or metastatic oesogastric adenocarcinoma
1 trial -
PRODIGE85-KANALRAD
CERO THERAPEUTICS HOLDINGS, INC.
locally advanced anal squamous cell carcinoma
1 trial -
ZOSTER ICO-N-2018-14
CERO THERAPEUTICS HOLDINGS, INC.
Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy
1 trial
Frequently asked questions
How many clinical projects does CERo Therapeutics have?
14 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.